natgillin/translations-raw huggingface dataset:
På grund af voldsom diurese medfører overdosis af hydrochlorthiazid elektrolytdepletering (hypokaliæmi, hypokloræmi, hyponatriæmi) og dehydrering. 
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloremia, hyponatraemia) and dehydration resulting from excessive diuresis.
Ifirmacombi indeholder natrium 
Ifirmacombi contains sodium
Jernoxid, gul (E172) Jernoxid, rød (E172) 
Iron oxide, yellow (E172)
Disse 24-timers resultater blev observeret uden at der opstod overdreven reduktion af blodtrykket på det maksimale niveau. 
These 24-hour effects were observed without excessive blood pressure lowering at peak and are consistent with safe and effective blood-pressure lowering over the once-daily dosing interval.
Ikke kendt: aplastisk anæmi, knoglemarvsdepression, neutropeni/agranulocytose, hæmolytisk anæmi, leukopeni, trombocytopeni 
Not known: aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
Hvis der er givet angiotensin II-receptor-antagonister under graviditetens andet trimester, anbefales ultralydskontrol af nyrefunktionen og kraniet. 
Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Når de to aktive stoffer i Ifirmacombi gives samtidigt, bliver deres virkning på blodtrykket større, end hvis de blev givet hver for sig. 
The two active ingredients in Ifirmacombi work together to lower blood pressure further than if either was given alone.
Doping-test: Indholdet af hydrochlorthiazid i dette lægemiddel kan medføre et positivt fund ved en doping-test. 
The hydrochlorothiazide contained in this medicine could produce a positive result in an anti-doping test.
Derfor frarådes kombination af lithium og Ifirmacombi (se pkt. 
Therefore, the combination of lithium and Ifirmacombi is not recommended (see section 4.4).
Beskyt huden mod sollys og UVstråler, mens du tager Ifirmacombi hvis du samtidig tager et af følgende lægemidler til behandling af for højt blodtryk: - en ACE-hæmmer (f.eks. enalapril, lisinopril, ramipril), især hvis du har nyrerproblemer i forbindelse med sukkersyge - aliskiren 
- if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems - Aliskiren
Ifirmacombi er ikke indiceret til patienter med svært nedsat leverfunktion. 
Ifirmacombi is not indicated in patients with severe hepatic impairment.
Ved ambulant blodtrykskontrol medførte kombinationen af 150 mg irbesartan og 12,5 mg hydrochlorthiazid, 1 gang dagligt, en vedvarende blodtryksreduktion over en 24 timers periode med en gennemsnitlig 24 timers placebo-korrigeret systolisk/diastolisk reduktion på 15,8/10,0 mmHg. 
When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebo-subtracted systolic/diastolic reductions of 15.8/10.0 mmHg.
Ved hypotension lægges patienten i rygleje, og salt- og væsketilskud administreres straks. 
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
Ikke kendt:sjældne tilfælde af overfølsomhedsreaktioner som fx angioødem, udslæt og urticaria 
Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria
Data fra kliniske studier har vist, at dobbelthæmning af renin-angiotensin-aldosteronsystemet (RAAS) ved kombinationsbehandling med ACE-hæmmere, angiotensin II-receptorantagonister eller aliskiren, er forbundet med en højere hyppighed af bivirkninger som hypotension, hyperkaliæmi og nedsat nyrefunktion (inklusive akut nyresvigt) sammenlignet med brug af et enkelt RAAS-virkende lægemiddel (se pkt. 
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).
Brug af anden medicinsammen med Ifirmacombi Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Ifirmacombi 300 mg/25 mg filmovertrukne tabletter EU/1/11/673/017-024 
Ifirmacombi 300 mg/25 mg film-coated tablets EU/1/11/673/017-024
Som det er tilfældet med ACE-hæmmere, kan samtidig anvendelse af angiotensin-II-antagonister og NSAID'ere medføre øget risiko for forværring af nyrefunktionen, herunder muligt akut nyresvigt samt øgning af serum-kalium. 
As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Faldet i SeSBT/SeDBT efter 5 uger var henholdsvis 30,8/24,0 mmHg og 21,1/19,3 mmHg for irbesartan/hydrochlorothiazid og irbesartan (p < 0,0001). 
The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p < 0.0001).
Irbesartans farmakokinetik er i kliniske forsøg ikke blevet påvirket af hydrochlorthiazid. 
In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Ved konstateret graviditet skal behandling med AIIRA seponeres øjeblikkeligt, og hvis det skønnes hensigtsmæssigt skal anden behandling iværksættes (se pkt. 
When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Spædbørn, hvis mødre har taget angiotensin II-receptor-antagonister, skal observeres omhyggeligt for hypotension (se pkt. 
Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).
Natrium: 
Sodium:
Ikke kendt: svimmelhed, paræstesier, uklarhed, rastløshed 
Not known: vertigo, paraesthesia, light-headedness, restlessness
Almindelige bivirkninger (kan påvirke op til 1 ud af 10 patienter) kvalme/opkastning unormal vandladning træthed svimmelhed (også når man rejser sig fra liggende eller siddende stilling) blodprøver, der viser en forhøjet mængde af et enzym, der måler muskel- og hjertefunktionen (kreatinkinase) eller stigning i stoffer, som måler nyrefunktionen (carbamid, kreatinin). 
Common side effects (may affect up to 1 in 10 people): - nausea/vomiting - abnormal urination - fatigue - dizziness (including when getting up from a lying or sitting position) - blood tests may show raised levels of an enzyme that measures the muscle and heart function
Kontakt lægen, før du tager Ifirmacombi, hvis du oplever følgende: hvis du får hyppig opkastning eller diarré hvis du lider af nyreproblemer eller er nyretransplanteret hvis du lider af hjerteproblemer hvis du lider af leverproblemer hvis du lider af sukkersyge hvis du lider af erytematøs lupus (også kaldet lupus eller SLE) hvis du lider af primær aldosteronisme (tilstand med høj produktion af hormonet aldosteron, som gør, at der ophobes natriumsalt i kroppen, og blodtrykket derfor stiger) hvis du har haft hudkræft, eller hvis du udvikler en uventet hudlæsion under behandlingen. 
Warnings and precautions Talk to your doctor before taking Ifirmacombi and if any of the following apply to you: - if you get excessive vomiting or diarrhoea - if you suffer from kidney problems or have a kidney transplant - if you suffer from heart problems - if you suffer from liver problems - if you suffer from diabetes - if you suffer from lupus erythematosus (also known as lupus or SLE) - if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
Dosisjustering af Ifirmacombi til ældre patienter er ikke nødvendig. 
No dosage adjustment of Ifirmacombi is necessary in older people.
Ikke kendt: hyperkalæmi 
Not known: hyperkalaemia
Polyvinylalcohol Titandioxid (E171) Macrogol 
Titanium dioxide (E171)
Ifirmacombi må ikke anvendes til patienter med alvorlig nyrefunktionsnedsættelse (kreatininclearance < 30 ml/min) (se pkt. 
Ifirmacombi should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
Dosisjustering af Ifirmacombi til patienter med let eller moderat leverfunktionsnedsættelse er ikke nødvendig (se pkt. 
No dosage adjustment of Ifirmacombi is necessary in patients with mild to moderate hepatic impairment (see section 4.3).
Ifirmacombi 300 mg/12,5 mg filmovertrukne tabletter EU/1/11/673/009-016 
Ifirmacombi 300 mg/12.5 mg film-coated tablets EU/1/11/673/009-016
Ifirmacombi 150 mg/12.5 mg filmovertrukne tabletter EU/1/11/673/001-008 
Ifirmacombi 150 mg/12.5 mg film-coated tablets EU/1/11/673/001-008
4.4), hyperurikæmi, glukosuri, hyperglykæmi, stigning i kolesterol og triglycerider 
Not known: electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides
Forholdet mellem den laveste og den maksimale effekt var henholdsvis 68% og 76% for Ifirmacombi 150 mg /12,5 mg og Ifirmacombi 300 mg/12,5 mg, når virkningen blev målt med blodtryksmanchet ved kontrolbesøg. 
The trough to peak effects measured by cuff during office visits were 68% and 76% for Ifirmacombi 150 mg/12.5 mg and Ifirmacombi 300 mg/12.5 mg, respectively.
For risikopatienter anbefales passende monitorering af serum-kalium (se pkt. 
Adequate monitoring of serum potassium in patients at risk is recommended (see section 4.4).
Den anbefalede dosis af Ifirmacombi 300 mg/25 mg er én tablet dagligt. 
The recommended dose of Ifirmacombi 300 mg/25 mg is one tablet a day.
Den anbefalededosis af Ifirmacombi 150 mg/12,5 mg er én tablet dagligt. 
The recommended dose of Ifirmacombi 150 mg/12.5 mg is one tablet a day.
EU/1/11/673/017 (14 filmovertrukne tabletter) EU/1/11/673/018 (28 filmovertrukne tabletter) EU/1/11/673/019 (30 filmovertrukne tabletter) EU/1/11/673/020 (56 filmovertrukne tabletter) EU/1/11/673/021 (56 x 1 filmovertrukne tabletter) EU/1/11/673/022 (84 filmovertrukne tabletter) EU/1/11/673/023 (90 filmovertrukne tabletter) EU/1/11/673/024 (98 filmovertrukne tabletter) 
EU/1/11/673/017 (14 film-coated tablets) EU/1/11/673/018 (28 film-coated tablets) EU/1/11/673/019 (30 film-coated tablets) EU/1/11/673/020 (56 film-coated tablets) EU/1/11/673/021 (56 x 1 film-coated tablets) EU/1/11/673/022 (84 film-coated tablets) EU/1/11/673/023 (90 film-coated tablets) EU/1/11/673/024 (98 film-coated tablets)
Dosering 1 gang dagligt med 150 mg irbesartan og 12,5 mg hydrochlorthiazid gav en systolisk/diastolisk gennemsnitlig placebojusteret blodtryksreduktion ved laveste måling (24 timer efter dosis) på 12,9/6,9 mmHg hos patienter med let til moderat hypertension. 
Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg in patients with mild-to-moderate hypertension.
EU/1/11/673/001 (14 filmovertrukne tabletter) EU/1/11/673/002 (28 filmovertrukne tabletter) EU/1/11/673/003 (30 filmovertrukne tabletter) EU/1/11/673/004 (56 filmovertrukne tabletter) EU/1/11/673/005 (56 x 1 filmovertrukne tabletter) EU/1/11/673/006 (84 filmovertrukne tabletter) EU/1/11/673/007 (90 filmovertrukne tabletter) EU/1/11/673/008 (98 filmovertrukne tabletter) 
EU/1/11/673/001 (14 film-coated tablets) EU/1/11/673/002 (28 film-coated tablets) EU/1/11/673/003 (30 film-coated tablets) EU/1/11/673/004 (56 film-coated tablets) EU/1/11/673/005 (56 x 1 film-coated tablets) EU/1/11/673/006 (84 film-coated tablets) EU/1/11/673/007 (90 film-coated tablets) EU/1/11/673/008 (98 film-coated tablets)
Bivirkninger, hvor hyppigheden ikke er kendt, er: hovedpine ringen for ørerne (tinnitus) hoste smagsforstyrrelser forstoppelse led-og muskelsmerter leversygdom og nedsat nyrefunktion øget indhold af kalium i blodet og allergiske reaktioner såsom udslæt, nældefeber, opsvulmet ansigt, læber, mund, tunge og hals der er i sjældne tilfælde også indberettet gulsot (gulfarvning af huden og/eller det hvide i øjnene). 
Undesirable effects where the frequency is not known are: - headache, - ringing in the ears, - cough, - taste disturbance, - indigestion, - pain in joints and muscles, - liver function abnormal and impaired kidney function, - increased level of potassium in your blood and - allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat.
4.4 og 4.6) - Alvorlig nyrefunktionsnedsættelse (kreatininclearance < 30 ml/min) - Refraktær hypokaliæmi, hyperkalcæmi - Alvorlig leverfunktionsnedsættelse, biliær cirrose og kolestase - Samtidig brug af Ifirmacombi og lægemidler indeholdende aliskiren er kontraindiceret hos patienter med diabetes mellitus eller nedsat nyrefunktion (GFR < 60 ml/min/1,73 m2) (se pkt. 
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance) - Second and third trimesters of pregnancy (see sections 4.4 and 4.6) - Severe renal impairment (creatinine clearance < 30 ml/min) - Refractory hypokalaemia, hypercalcaemia - Severe hepatic impairment, biliary cirrhosis and cholestasis - The concomitant use of Ifirmacombi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5
EU/1/11/673/009 (14 filmovertrukne tabletter) EU/1/11/673/010 (28 filmovertrukne tabletter) EU/1/11/673/011 (30 filmovertrukne tabletter) EU/1/11/673/012 (56 filmovertrukne tabletter) EU/1/11/673/013 (56 x 1 filmovertrukne tabletter) EU/1/11/673/014 (84 filmovertrukne tabletter) EU/1/11/673/015 (90 filmovertrukne tabletter) EU/1/11/673/016 (98 filmovertrukne tabletter) 
EU/1/11/673/009 (14 film-coated tablets) EU/1/11/673/010 (28 film-coated tablets) EU/1/11/673/011 (30 film-coated tablets) EU/1/11/673/012 (56 film-coated tablets) EU/1/11/673/013 (56 x 1 film-coated tablets) EU/1/11/673/014 (84 film-coated tablets) EU/1/11/673/015 (90 film-coated tablets) EU/1/11/673/016 (98 film-coated tablets)
Den anbefalede dosis af Ifirmacombi 300 mg/12,5 mg er én tablet dagligt. 
The recomended dose of Ifirmacombi 300 mg /12.5 mg is one tablet a day.
Ifirmacombi 300 mg/12,5 mg: mannitol, hydroxypropylcellulose, lav-substituteret hydroxypropylcellulose, natriumstivelsesglycolat, talcum, macrogol 6000, hydrogeneret ricinusolie i tabletkernen og polyvinylalcohol, titandioxid (E171), macrogol og talcum i filmovertrækket. 
Ifirmacombi 300 mg/12.5 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc in the film-coating.
Lægen vil sædvanligvis ordinere behandling med Ifirmacombi 300 mg/25 mg, hvis den tidligere behandling ikke sænkede dit blodtryk tilstrækkeligt. 
Ifirmacombi 300 mg/25 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Samtidig administration af irbesartan tenderer at ændre det kaliumtab, der er forbundet med disse diuretika, formodentligt ved at blokere renin-angiotensin-aldosteronsystemet. 
Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics.
Lægen vil sædvanligvis ordinere behandling med Ifirmacombi 150 mg/12,5 mg, hvis den tidligere behandling ikke sænkede dit blodtryk tilstrækkeligt. 
Ifirmacombi 150 mg/12.5 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Der er dog rapporteret minimal eller ingen effekt ved den dosis på 12,5 mg, som findes i Ifirmacombi. 
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in Ifirmacombi, minimal or no effects were reported.
Ifirmacombi 150 mg/12,5 mg: mannitol, hydroxypropylcellulose, lav-substituteret hydroxypropylcellulose, natriumstivelsesglycolat, talcum, macrogol 6000, hydrogeneret ricinusolie i tabletkernen og polyvinylalcohol, titandioxid (E171), macrogol, talcum, gul jernoxid (E172) og rød jernoxid (E172) i filmovertrækket. 
Ifirmacombi 150 mg/12.5 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172) and red iron oxide (E172) in the film-coating.
Det er især tilfældet ved nyrefunktionsnedsættelse og/eller hjerteinsufficiens og diabetes mellitus. 
Conversely, due to the irbesartan component of Ifirmacombi hyperkalaemia might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus.
Patienter, der planlægger at blive gravide, bør skiftes til anden antihypertensiv behandling, hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA skønnes nødvendig. 
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Ifirmacombi 150 mg/12,5 mg, 300 mg/12,5 mg og 300 mg/25 mg filmovertrukne tabletter indeholder: 
Ifirmacombi 150 mg/12.5 mg and 300 mg/25 mg film-coated tablets Film coating:
Dog skal denne faste dosis-kombination gives med forsigtighed til patienter med let til moderat nedsat nyrefunktion (kreatininclearance ≥ 30 ml/min, men < 60 ml/min). 
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but < 60 ml/min) this fixed dose combination should be administered with caution.
Lægen vil sædvanligvis ordinere behandling med Ifirmacombi 300 mg/12,5 mg, hvis den tidligere behandling ikke sænkede dit blodtryk tilstrækkeligt. 
Ifirmacombi 300 mg/12.5 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Et randomiseret, dobbeltblindt, aktivt kontrolleret, parallelt multicenterforsøg af 8 ugers varighed har evalueret virkningen og sikkerheden af kombinationen irbesartan og hydrochlorthiazid som initial behandling ved svær hypertension (defineret som SeDBT ≥ 110 mmHg). 
Efficacy and safety of the combination of irbesartan and hydrochlorothiazide as initial therapy for severe hypertension (defined as SeDBP ≥ 110 mmHg) was evaluated in a multicentre, randomized, double-blind, active-controlled, 8-week, parallel-arm study.
Ifirmacombi 300 mg/25 mg: mannitol, hydroxypropylcellulose, lav-substituteret hydroxypropylcellulose, natriumstivelsesglycolat, talcum, macrogol 6000, hydrogeneret ricinusolie i tabletkernen og polyvinylalcohol, titandioxid (E171), macrogol, talcum, gul jernoxid (E172) og rød jernoxid (E172) i filmovertrækket.Se punkt 2 ”Ifirmacombi indeholder natrium”. 
Ifirmacombi 300 mg/25 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172) and red iron oxide (E172) in the film-coating.
Ikke almindelig: rødme 
Uncommon: flushing
Der er hverken observeret rebound-hypertension for irbesartan eller hydrochlorthiazid. 
Although not specifically studied with the Ifirmacombi, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Sådan skal du tage Ifirmacombi 
How to take Ifirmacombi
150 mg med systematisk titrering (inden evaluering af responset på den lavere dosis) efter 1 uge til henholdsvis irbesartan/hydrochlorothiazid 300 mg/25 mg eller irbesartan 300 mg. 
A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically force titrated (before assessing the response to the lower dose) after one week to irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively.
Tilgængelige data fra epidemiologiske studier viser en kumulativ dosisafhængig forbindelse mellem hydrochlorthiazid og non-melanom hudkræft. 
Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed.
Det skal du vide, før du begynder at tage Ifirmacombi Sådan skal du tage Ifirmacombi Bivirkninger 
What Ifirmacombi is and what it is used for What you need to know before you take Ifirmacombi How to take Ifirmacombi
Dosis af Ifirmacombi 300 mg/25 mg: 
Dosage of Ifirmacombi 300 mg/25 mg
Ifirmacombi 300 mg/12,5 mg Hvide, bikonvekse, kapselformede, filmovertrukne tabletter (tabletter). 
Ifirmacombi 300 mg/12.5 mg White, biconvex, capsule shaped, film-coated tablets (tablets).
Ifirmacombi 150 mg/12,5 mg filmovertrukne tabletter Svagt lyserøde, bikonvekse, ovale, filmovertrukne tabletter. 
Ifirmacombi 150 mg/12.5 mg film-coated tablets Pale pink, biconvex, oval, film-coated tablets.
Ifirmacombi 150 mg/12,5 mg filmovertrukne tabletter Ifirmacombi 300 mg/12,5 mg filmovertrukne tabletter Ifirmacombi 300 mg/25 mg filmovertrukne tabletter 
Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets
Forholdet mellem den laveste og den maksimale effekt af Ifirmacombi 150 mg/12,5 mg var 100%, når blodtrykket blev monitoreret ambulant. 
When measured by ambulatory blood pressure monitoring, the trough to peak effects of Ifirmacombi 150 mg/12.5 mg were 100%.
Irbesartans farmakokinetiske parametre ændres ikke væsentligt hos patienter med let/moderat cirrose. 
In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Ifirmacombi 300 mg/12,5 mg filmovertrukne tabletter Hvide, bikonvekse, kapselformede, filmovertrukne tabletter. 
Ifirmacombi 300 mg/12.5 mg film-coated tablets White, biconvex, capsule shaped, film-coated tablets.
Ifirmacombi 300 mg/25 mg filmovertrukne tabletter Svagt lyserøde, bikonvekse, kapselformede, filmovertrukne tabletter. 
Ifirmacombi 300 mg/25 mg film-coated tablets Pale pink, biconvex, capsule shaped, film-coated tablets.
Ifirmacombi 300 mg/12,5 mg kan gives til patienter, der er utilstrækkeligt regulerede med irbesartan 300 mg eller med Ifirmacombi 150 mg/12,5 mg. 
- Ifirmacombi 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; - Ifirmacombi 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Ifirmacombi 150 mg/12.5 mg. - Ifirmacombi 300 mg/25 mg may be administered in patients insufficiently controlled by Ifirmacombi 300 mg/12.5 mg.
Ifirmacombi 150 mg/12,5 mg filmovertrukne tabletter Ifirmacombi 300 mg/12,5 mg filmovertrukne tabletter Ifirmacombi 300 mg/25 mg filmovertrukne tabletter Irbesartan/hydrochlorthiazid 
Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets Irbesartan/Hydrochlorothiazide
Hver filmovertrukket tablet indeholder 300 mg irbesartan (som irbesartanhydrochlorid) og 25 mg hydrochlorthiazid. 
Each film-coated tablet contains 300 mg irbesartan (as irbesartan hydrochloride) and 25 mg hydrochlorothiazide.